应世生物拟港股上市 中国证监会要求补充说明股权变动与股东情况等事项

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for five companies, including Yingshi Biotechnology, which is preparing for an IPO in Hong Kong. The CSRC has requested clarifications on various compliance and operational matters related to the company's offshore structure and shareholder changes [1][2]. Group 1: Compliance and Regulatory Requirements - The CSRC requires Yingshi Biotechnology to clarify the compliance of its offshore structure and return investment, including details on foreign exchange management, overseas investment, and tax management [1]. - The company must provide a legal opinion on the pricing basis and payment methods for acquiring domestic operating entities, ensuring compliance with regulations regarding foreign investment mergers [1][2]. - The CSRC has requested a review of the stock options granted to external consultants and the legality of shareholder structures, particularly regarding any prohibited entities [2]. Group 2: Shareholder and Equity Changes - Yingshi Biotechnology is required to explain the rationale behind the recent equity changes, including the pricing of new shareholders and any discrepancies in investment amounts [2]. - The company must clarify the reasons for capital reduction in its Nanjing entity and ensure compliance with relevant laws regarding capital contributions and tax payments [2][3]. - A review of historical equity changes in the domestic operating entities is necessary to confirm their legality and compliance with regulations [3]. Group 3: Business Operations - The company must detail its business scope and operations, particularly regarding its involvement in human stem cells and gene therapy, ensuring compliance with foreign investment policies [3]. - Financial data, including net asset figures, must be supplemented in the filing report to meet regulatory requirements [3]. - The company is required to explain any inconsistencies between the issuance plan and the materials submitted for the IPO [3]. Group 4: Product Pipeline and Innovation - Yingshi Biotechnology's product pipeline includes ifebemtinib, a highly selective FAK inhibitor nearing commercialization, with multiple clinical projects in China and breakthrough therapy designations from NMPA and FDA [4]. - The pipeline also features IN10028, a second-generation selective FAK inhibitor, and three innovative antibody-drug conjugates (ADCs) targeting tumor microenvironments and enhancing treatment efficacy [4].